Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA

Neoplasia (United States)

Volumn 15, Issue 1, 2013, Pages 95-101

  Jin, Guangfu ^a   Zheng, Siqun Lilly ^a   Lilja, Hans ^b,c   Kim, Seong Tae ^a   Tao, Sha ^a   Gao, Zhengrong ^a   Young, Tracey ^a   Wiklund, Fredrik ^b,c   Feng, Junjie ^a   Isaacs, William B ^d   Rittmaster, Roger S ^e   Gronberg, Henrik ^f   Condreay, Lynn D ^e   Sun, Jielin ^a   Xu, Jianfeng ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c LUND UNIVERSITY   (Sweden)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e GLAXOSMITHKLINE   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; ATF7IP GENE; CANCER RISK; CHROMOSOME 12P; CHROMOSOME 13; CHROMOSOME 19Q; CONTROLLED STUDY; ENZYME IMMUNOASSAY; GENE; GENE FREQUENCY; GENE LOCUS; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; GLEASON SCORE; HUMAN; KLK2 GENE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84873047405     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121620     Document Type: Article

References (30)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al. (2012). Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366, 981-990.
2. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, and Lilja H (2010). Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11, 725-732.
3. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, et al. (2012). Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104, 125-132.
4. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, and de Koning H (2009). Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101, 374-383.
5. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, and Kane RL (2008). Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148, 435-448.
6. Vickers AJ, Cronin AM, Bjork T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, and Lilja H (2010). Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341, c4521.
7. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, and Coltman CA Jr (2005). Operating characteristics of prostatespecific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294, 66-70.
8. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, et al. (2009). Prostate specific antigen best practice statement: 2009 update. J Urol 182, 2232-2241.
9. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P, and Allen NE (2005). Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48, 386-399; discussion 398-389.
10. Stephan C, Jung K, LeinM, Sinha P, SchnorrD, and Loening SA (2000). Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 9, 1133-1147.
11. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M, and Rittmaster R (2004). Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172, 1314-1317.
12. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, et al. (2010). Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362, 1192-1202.
13. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Balter K, et al. (2008). Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358, 910-919.
14. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, and Lovgren T (1995). Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 41, 1115-1120.
15. Marchini J, Howie B, Myers S, McVean G, and Donnelly P (2007). A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 39, 906-913.
16. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, and Reich D (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38, 904-909.
17. Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, Agnarsson BA, Benediktsdottir KR, Isaksson HJ, Kostic JP, et al. (2010). Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2, 62ra92.
18. Christensson A, Laurell CB, and Lilja H (1990). Enzymatic activity of prostatespecific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194, 755-763.
19. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, and Lovgren T (1991). Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37, 1618-1625.
20. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, et al. (2008). Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40, 316-321.
21. Nam RK, Zhang WW, Klotz LH, Trachtenberg J, Jewett MA, Sweet J, Toi A, Teahan S, Venkateswaran V, Sugar L, et al. (2006). Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Cancer Res 12, 6452-6458.
22. Nam RK, Zhang WW, Trachtenberg J, Diamandis E, Toi A, Emami M, Ho M, Sweet J, Evans A, Jewett MA, et al. (2003). Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol 21, 2312-2319.
23. Klein RJ, Hallden C, Cronin AM, Ploner A, Wiklund F, Bjartell AS, Stattin P, Xu J, Scardino PT, Offit K, et al. (2010). Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) 3, 611-619.
24. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, and Saedi MS (1997). Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 57, 3111-3114.
25. Lovgren J, Rajakoski K, Karp M, Lundwall A, and Lilja H (1997). Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238, 549-555.
26. Takayama TK, Fujikawa K, and Davie EW (1997). Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 272, 21582-21588.
27. Williams SA, Xu Y, De Marzo AM, Isaacs JT, and Denmeade SR (2010). Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. Prostate 70, 788-796.
28. Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, Ricketts M, Linger R, Nsengimana J, Deloukas P, et al. (2010). Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet 42, 604-607.
29. Liu L, Ishihara K, Ichimura T, Fujita N, Hino S, Tomita S, Watanabe S, Saitoh N, Ito T, and Nakao M (2009). MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity. J Biol Chem 284, 5165-5174.
30. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A, Jakobsdottir M, Helgadottir H, Thorlacius S, Aben KK, et al. (2009). Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 41, 221-227.